REGN

Regeneron Pharmaceuticals
D

REGN

Arincen73/100B

Regeneron Pharmaceuticals stock buybacks 1991–2026

Regeneron Pharmaceuticals spent 399.70M USD buying back its shares in Q3 FY2026, the three months to 30 September 2026, down 39.8% on the same quarter a year before. Regeneron Pharmaceuticals spent 3.04B USD buying back its shares over the last twelve months, down 18.9% on the twelve months before. In fiscal year 2025 it spent 3.97B USD, up 9.3% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Stock buybacks

Growth

Fiscal yearPeriod endingStock buybacksGrowthDividends paidFree cash flow
TTM30 Sept 20263.04B-18.94%383.00M3.59B
FY202531 Dec 20253.97B+9.31%370.30M4.08B
FY202431 Dec 20243.63B+62.52%0.003.66B
FY202331 Dec 20232.24B-11.61%0.003.67B
FY202231 Dec 20222.53B-5.59%0.004.42B
FY202131 Dec 20212.68B-58.97%0.006.53B
FY202031 Dec 20206.53B+1,307.11%0.002.00B
FY201931 Dec 2019463.90M+142.12%0.002.00B
FY201831 Dec 2018191.60M-36.49%0.001.81B
FY201731 Dec 2017301.70M+110.68%0.001.03B
FY201631 Dec 2016143.20M-10.80%0.00974.00M
FY201531 Dec 2015160.54M-40.01%0.00652.85M
FY201431 Dec 2014267.58M+37.16%0.00419.43M
FY201331 Dec 2013195.09M+19.47%0.00432.27M
FY201231 Dec 2012163.30M+551.17%0.00-123.95M
FY201131 Dec 201125.08M+560.29%0.00-198.90M
FY201031 Dec 20103.80M—0.00-3.35M
FY200931 Dec 20090.00—0.00-169.55M
FY200831 Dec 20080.00—0.00-123.94M
FY200731 Dec 20070.00—0.008.93M
FY200631 Dec 20060.00—0.0020.26M
FY200531 Dec 20050.00-100.00%0.00-35.26M
FY200431 Dec 2004888.00K—0.00-23.08M
FY200331 Dec 20030.00—0.00-35.79M
FY200231 Dec 20020.00—0.00-144.89M
FY200131 Dec 20010.00—0.00-65.54M
FY200031 Dec 20000.00—0.00-34.41M
FY199931 Dec 19990.00—0.00-19.50M
FY199831 Dec 19980.00—0.00-13.20M
FY199731 Dec 19970.00—0.00-8.20M
FY199631 Dec 19960.00—0.00-28.90M
FY199531 Dec 19950.00—0.00-21.50M
FY199431 Dec 19940.00—0.00-27.40M
FY199331 Dec 19930.00—0.00-40.30M
FY199231 Dec 19920.00—0.00-19.30M
FY199131 Dec 19910.00—0.00-7.80M

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

The money spent buying back the company's own shares in each period, from the cash flow statement.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow

Common questions about Regeneron Pharmaceuticals's buybacks

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.